Sandoz releases positive results for biosimilar aflibercept in MYLIGHT Phase III study

News
Article

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

A doctor looks into a microscope with a digital output of figures and numbers superimposed over her.  Image credit: ©Teerayut – stock.adobe.com

The biologic serves to improve and maintain visual acuity in patients with neovascular retinal diseases. Image credit: ©Teerayut – stock.adobe.com

Sandoz, a division of Novartis, announced positive results from the MYLIGHT (NCT04864834) Phase III study, a confirmatory efficacy and safety study for its biosimilar aflibercept. The company, based in Basel, Switzerland, shared the outcomes on Monday. Sandoz is expected to file for regulatory approval for biosimilar aflibercept in the EU and US later this year.

In a comprehensive development programme, the biosimilar aflibercept met its primary efficacy endpoint.1 A press release from Novartis indicated that the biosimilar aflibercept showed therapeutic equivalence in mean change of best corrected visual acuity (BCVA) in comparison to the reference biologic, Eylea®. Within the trial period, researchers reported no clinically meaningful difference in immunogenicity, pharmacokinetics or safety.

Like the reference product, biosimilar aflibercept is a therapeutic for patients with conditions such as neovascular age-related macular degeneration (nAMD) and macular oedema. The biologic serves to improve and maintain visual acuity in patients with these and other neovascular retinal diseases.1

Claire D’Abreu-Hayling, chief scientific officer of Sandoz, acknowledged the positive outcome of the study. “This important milestone, confirming therapeutic equivalence of the biosimilar aflibercept with the reference biologic, takes us one step closer to providing patients with a key treatment in an area of high unmet need within ophthalmology,” she said in a statement.

Reference

  1. Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept. News release. Novartis, August 15, 2023. Accessed August 15, 2023. https://www.novartis.com/news/media-releases/sandoz-announces-positive-results-from-mylight-phase-lll-study-biosimilar-aflibercept

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.